Redx Pharma is a drug discovery and development company formed in 2010. It is focused on improving the characteristics of existing drug classes to create new drugs in the areas of cancer, immunology and infection. The company's work has been endorsed by partnerships with global pharmaceutical companies and the NHS.

Find out more

Latest News

Interim Results for the six months ended 31 March 2017
17 May 2017

Redx (AIM: REDX) announces its interim results for the six months ended 31 March 2017:

  • Clinical trial application filed for Porcupine inhibitor RXC004
  • Development candidate chosen for reversible BTK inhibitor RXC005 for drug resistant chronic lymphocytic leukaemia
  • Strategic restructuring completed post period; estimated £4.2 million annual cost saving
  • Iain Ross appointed as Non-Executive Chairman of the Board from 1 May 2017
  • £12 million gross raised in March 2017, including a subscription with a related sharing agreement

Read more

In The Media

17 May 2017
Redx Pharma “in a very good place with great assets”

31 Mar 2017
US$1mln grant is ‘testament to the great science’ ongoing at Redx, CSO says

21 Mar 2017
Redx Pharma to refocus on key assets